Secukinumab showed sustained efficacy in psoriasis

AMSTERDAM – The investigational biologic agent secukinumab continued to show strong efficacy through 52 weeks of treatment in a new secondary analysis of the pivotal phase III ERASURE trial. For...

Field of Interest: Dermatology
Type: News Item

In psoriasis, is pushing for PASI 90 really worthwhile?

AMSTERDAM – Does pushing for a PASI 90 response instead of settling for a PASI 75 matter to patients being treated for moderate-to-severe chronic plaque psoriasis? You bet it does, Dr. Mark G....

Field of Interest: Dermatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.